Nutra Pharma Corp (NPHC)

[cngreen]

1. Nutra Pharma owns over 20 patents and trademarks as well as 119 internet domains.

2. These patents are built around their development of treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenoleukodystrophy(ALS), Adrenomyeloneuropathy(AMN), Rheumatoid Arthritis (RA), Pain, and Myasthenia Gravis (MG).

3. Nutra Pharma is already generating revenue with their Nyloxin®, Pet Pain-Away, and Equine Pain-Away in the over-the-counter pain management market, selling on different platforms such as Amazon, Walmart, and etc. They are selling worldwide in India as well.

4. Already granted Orphan Drug Status on their lead drug RPI-78M for treating Multiple Sclerosis in children.

5. All their drugs have completed Phase I trial and are ready for next phases II/III.

6. They have been working with private laboratories and governmental agencies to move forward their Nerve Agent Countermeasures and technology. Government grants and contracts are coming as stated in the shareholders letter by company.

7. Research partnership and funding to be announced regarding their lead drug RPI-78M for Multiple Sclerosis, HIV, ALS/AMN

8. Getting Current!!

9. Scaling up production to meet expected upcoming orders